The seventh batch of national pharmaceutical collection has launched the newly added regional rules to respond to the risk of illegal regulations for pharmaceutical companies

On June 20, Shanghai Sunshine Pharmaceutical Procurement Network released the "National Pharmaceutical Pharmaceutical Procurement Documents (GY-YD2022-1)", and the seventh batch of national collection was officially launched.

Different from the 58 varieties and 208 rules disclosed during the previous batch of national collection information, the latest procurement documents show that this collection involves 147 specifications of 61 varieties. It is worth noting that in this collection list, it involves a large single product with a sales scale of over 1 billion yuan in the sales scale of more than 1 billion yuan.

Deng Zhidong, general manager of Hainan Boao Medical, told a reporter from the Securities Daily that there are more than 500 drug varieties in the national level clearly clearing the "14th Five -Year Plan" planning period. After the completion of this collection, there will be nearly 300 categories of drugs. The announcement of the 61 drugs will further expand the acceleration of medical insurance collection.

In early June, the National Medical Insurance Administration officially announced that in the video conference on the analysis of the centralized procurement situation and key work promotion of the centralized procurement situation held on June 9, it mentioned the seventh batch of national collection. The news was once considered to be an important signal for the seventh batch of national collection work.

On June 20, the seventh batch of national collection documents was officially released. Compared with the previous collection, the national collection rules were added to the regional and alternative enterprises. The rules require that in addition to the selection of the middle -elected area, pharmaceutical companies must also choose to prepare for the region.

The document clearly states that after the main region of the main supply area is confirmed, the proposed enterprise needs to be confirmed by the regional confirmation of the region. And the preparation area of ​​each proposed enterprise must be different from its main region. In terms of market supply, when the main enterprise cannot meet the market demand of the selected areas, the preparation enterprise can obtain the owner's identity in accordance with the relevant procedures. The selected enterprises need to be supplied directly in the area of ​​the preparation area according to the selected price.

An industry practitioner told the Securities Daily reporter that in recent years, many companies have violated the regulations on the supply of drugs. For example, in January 2022, the Greyli slices produced by St. Jitang were disqualified from the selection of selection because they did not meet the quality management specifications of drug production.

The above -mentioned industry persons pointed out that the regional policy launched this time is to solve the problem of supply guarantee of related drugs after solving violations of pharmaceutical companies from the institutional level.

Deng Zhidong, general manager of Hainan Boao Medical, told the Securities Daily reporter that there are many products in the National Pharmaceutical Collection, rich in categories, involving tumors, mental illness, gastrointestinal diseases, Alzheimer disease, influenza, anti -inflammatory and other categories. Different from the past, the large varieties of drugs in this collection catalog are prominent. Olyvas, the U.S. Diamond Pharium, and Phard Pyrine Hydrochloride, and the large varieties of large varieties of nifed, have been included in the collection catalog, which has become a key category of this collection.

From the perspective of collecting documents, in this national collection, a maximum of 10 shortlisted enterprises were shortlisted. According to reporters, there are 12 drugs in the national collection of drugs involving more than 10 drugs through consistency evaluation companies. Taking Omeprazole injection as an example, there are currently 27 generic drug reviews. In addition to the former research manufacturer Astrikon, 28 companies will compete with 28 companies on the same stage. Compared with the past, the competition in this collection is even more intense.

According to the collection of collection documents, the medicines that obtain effective registration and approval before July 7 meet the collection conditions. That is, in the next ten days, it will be the final window period for related pharmaceutical companies to participate in this round of collection. If there are effective registration approval of enterprise products, the number of competing companies in related products will be further increased.

In addition, the above -mentioned industry practitioners pointed out that this round of collection involves a variety of injections. The main sales channels for injection are carried out in the hospital. If they cannot obtain qualifications, they will have a great impact on the sales of enterprise drugs. Therefore, comprehensively, this collection will further exacerbate the competition between pharmaceutical companies.

Deng Zhidong said that the further promotion of Jicai has caused a certain impact and impact on drug prices and pharmaceutical companies' revenue. If pharmaceutical companies want to develop long -term development, they need to update and optimize the development strategy of the enterprise, clarify the development goals and business models, find market positioning and target customer base, and provide higher -level and more diversified high -quality services.

- END -